Evidence map›Paper›PMID 38474935›Full record

ArticleSensors (Basel, Switzerland)2024

Acceleration of Hyperspectral Skin Cancer Image Classification through Parallel Machine-Learning Methods.

Bernardo Petracchi, Emanuele Torti, Elisa Marenzi, Francesco Leporati

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bernardo PetracchiDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, I-27100 Pavia, Italy.ORCID 0009-0000-4685-961X
Emanuele TortiDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, I-27100 Pavia, Italy.ORCID 0000-0001-8437-8227
Elisa MarenziDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, I-27100 Pavia, Italy.
Francesco LeporatiDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, I-27100 Pavia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperspectral imaging (HSI) has become a very compelling technique in different scientific areas; indeed, many researchers use it in the fields of remote sensing, agriculture, forensics, and medicine. In the latter, HSI plays a crucial role as a diagnostic support and for surgery guidance. However, the computational effort in elaborating hyperspectral data is not trivial. Furthermore, the demand for detecting diseases in a short time is undeniable. In this paper, we take up this challenge by parallelizing three machine-learning methods among those that are the most intensively used: Support Vector Machine (SVM), Random Forest (RF), and eXtreme Gradient Boosting (XGB) algorithms using the Compute Unified Device Architecture (CUDA) to accelerate the classification of hyperspectral skin cancer images. They all showed a good performance in HS image classification, in particular when the size of the dataset is limited, as demonstrated in the literature. We illustrate the parallelization techniques adopted for each approach, highlighting the suitability of Graphical Processing Units (GPUs) to this aim. Experimental results show that parallel SVM and XGB algorithms significantly improve the classification times in comparison with their serial counterparts.

Indexed as

AlgorithmsSkin NeoplasmsAccelerationHumansHyperspectral ImagingMachine LearningSupport Vector MachineeXtreme gradient boostingGPUhyperspectral imagingmachine learningrandom forestsupport vector machine

Identifiers

PMID38474935
PMCPMC10934987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.